Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Different from tamsulosin hydrochloride and silodosin, in that it has higher and extremely higher affinity resp...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132093/ |